UnknownPhase NA

Ghrelin Effect on Beta Cell Function in Health and Disease

Lead sponsor

David Dalessio

Asset

Avexitide

Listed sites

Recruiting sites

Estimated enrollment

Study population

Eligibility highlights

•BMI 18-29•Healthy volunteers

Primary endpoint

Registered trial locations

Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT01729299

Org study ID12070904

Timeline

Milestones

Study first posted2012-11-20estimated

Last update posted2013-04-04estimated

Study start2013-04 (month precision)

Primary completion2014-04estimated (month precision)

Study completion2014-04estimated (month precision)

Assets

Investigational agents

Avexitide

Who can enroll

Minimum age18 Years

Maximum age45 Years

SexAll

Healthy volunteersAccepted

Inclusion criteria

1. Healthy men and women

2. Ages between 18 and 45 years

3. BMI between 18 and 29 kg/m2

Exclusion criteria

1. History or clinical evidence of impaired fasting glucose or diabetes mellitus, myocardial infarction within the past year, history or symptoms of congestive heart failure, uncontrolled hypertension, history or active liver or renal disease (AST or ALT >2x upper limits of normal, calculated glomerular filtration rate [GFR] <60).

2. History of pituitary or adrenal disorders or neuroendocrine tumor.

3. Anemia defined as hematocrit <33%.

4. Use of medications that alter glucose metabolism

5. Pregnancy or lactation.

6. Abnormal Electrocardiogram (ECG): evidence of ischemia or arrhythmia.

7. Women who have a positive pregnancy test at any time during the study period.

Endpoints (0)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

No endpoints recorded for this trial.

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 6, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 6, 2026 snapshot.